



DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 East William Street, Suite 101
Carson City, Nevada 89701
Telephone (775) 684-3676 • Fax (775) 687-3893
<http://dhcfp.nv.gov>

**NOTICE OF MEETING TO SOLICIT PUBLIC COMMENTS AND INTENT TO
ACT UPON AMENDMENTS TO THE NEVADA MEDICAID OPERATIONS
MANUANL (MOM) AND MEDICAID SERVICES MANUALS (MSM)**

AGENDA

- Date of Publication:** September 25, 2019
- Date and Time of Meeting:** October 29, 2019 at 9:10 AM or upon completion of the amendments to the State Plan for Medicaid Services public hearing
- Name of Organization:** The State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP)
- Place of Meeting:** Nevada State Legislative Building
401 S. Carson Street, Room 3137
Carson City, Nevada 89701
- Place of Videoconference** Grant Sawyer Office Building
555 E. Washington Avenue, Room 4412E
Las Vegas, Nevada 89101
- Teleconference:** (888) 363-4735
- Access Code:** 1961395

AGENDA

1. General Public Comments (Because of time considerations, the period for public comment by each speaker or organization may be limited to three minutes and speakers are urged to avoid repetition of comments made by previous speakers.)
2. For possible action: Discussion and adoption of changes to MOM Chapter 200 – Boards, Committees and Advisory Committees

The DHCFP is proposing revisions to MOM Chapter 200 to align with the provisions of Senate Bill 378. The proposed revisions consist of changing the name of the Pharmacy and Therapeutics (P&T) Committee to Silver State Scripts Board, updating policy allowing discussions associated with cost for prescription drugs on the Nevada Medicaid Preferred Drugs List, updating the DHHS Director as the appointing authority for members of the Silver State Scripts Board, removing restrictions concerning the numbers of members of the Silver State Scripts Board, and lastly updating the title of the Board Coordinator to DHHS Senior Advisor on Pharmacy.

Entities Financially Affected: Providers who prescribe, dispense or administer drugs may be affected by this change, including but not limited to the following Provider Types (PTs):

Outpatient Surgery (PT 10); Hospital, Inpatient (PT 11); Hospital, Outpatient (PT 12); Intermediate Care Facilities for Individuals with Intellectual Disabilities, Public (PT 16); Special Clinics (PT 17); Nursing Facility (PT 19); Physician/Osteopath (PT 20); Podiatrist (PT 21); Advanced Practice Registered Nurse (PT 24); Pharmacy (PT 28); Home Health Agency (PT 29); Ambulatory Surgical Centers, Freestanding (PT 46); Indian Health Programs and Tribal Clinics (PT 47); Indian Health Service Hospital, Inpatient (Tribal) (PT 51), Indian Health Service Hospital, Outpatient (Tribal) (PT 52); Transitional Rehabilitative Center, Outpatient (PT 55); Inpatient Rehabilitation and Long Term Acute Care (LTAC) Specialty Hospitals (PT 56); Hospice (PT 64); Hospice, Long Term Care (PT 65); Intermediate Care Facilities for Individuals with Intellectual Disabilities, Private (PT 68); Nurse Anesthetist (PT 72); Critical Access Hospital (CAH), Inpatient (PT 75); Audiologist (PT 76); Physician's Assistant (PT 77); Indian Health Service Hospital, Inpatient (Non-Tribal) (PT 78); Indian Health Service Hospital, Outpatient (Non-Tribal) (PT 79).

Financial impact on local government: There is no financial impact on local government.

Effective date: October 30, 2019.

- a. Presentation of MOM Chapter 200
 - b. Public comment on proposed changes
 - c. Adoption of proposed changes
3. For possible action: Discussion and adoption of changes to MSM Chapter 1200 – Prescribed Drugs

The DHCFP proposes revisions to MSM Chapter 1200, Appendix A, to update the age in existing prior authorization criteria for Kalydeco® (ivacaftor) from “one year of age and older” to “six months of age and older” and Symdeko® (tezacaftor/ivacaftor) from “12 years of age and older” to “six years of age and older” based on updated Federal Drug Administration (FDA) approved indications.

Entities Financially Affected: Providers who prescribe, dispense or administer this drug may be affected by this change, including but not limited to the following Provider Types (PTs):

Outpatient Surgery (PT 10); Hospital, Inpatient (PT 11); Hospital, Outpatient (PT 12); Intermediate Care Facilities for Individuals with Intellectual Disabilities, Public (PT 16); Special Clinics (PT 17); Nursing Facility (PT 19); Physician/Osteopath (PT 20); Podiatrist (PT 21); Advanced Practice Registered Nurse (PT 24); Pharmacy (PT 28); Home Health Agency (PT 29); Ambulatory Surgical Centers, Freestanding (PT 46); Indian Health Programs and Tribal Clinics (PT 47); Indian Health Service Hospital, Inpatient (Tribal) (PT 51), Indian Health Service Hospital, Outpatient (Tribal) (PT 52); Transitional Rehabilitative Center, Outpatient (PT 55); Inpatient Rehabilitation and Long Term Acute Care (LTAC) Specialty Hospitals (PT 56); Hospice (PT 64); Hospice, Long Term Care (PT 65); Intermediate Care Facilities for Individuals with Intellectual Disabilities, Private (PT 68); Nurse Anesthetist (PT 72); Critical Access Hospital (CAH), Inpatient (PT 75); Audiologist (PT 76); Physician's Assistant (PT 77); Indian Health Service Hospital, Inpatient (Non-Tribal) (PT 78); Indian Health Service Hospital, Outpatient (Non-Tribal) (PT 79).

Financial impact on local government: There is no financial impact on local government.

Effective date: November 4, 2019.

- a. Presentation of MSM Chapter 1200
- b. Public comment on proposed changes
- c. Adoption of proposed changes

4. Adjournment

Nevada Medicaid is unaware of any financial impact to other entities or local government due to this public hearing, other than as stated above.

PLEASE NOTE: Items may be taken out of order. Items may be pulled or removed from the agenda at any time. All public comment may be limited to three minutes.

The DHCFP is exempt from Chapter 233B according to NRS 233B.039 and is not required to comply with the open meeting law in this process.

This notice and agenda have been posted at <http://dhcfp.nv.gov/> and <https://notice.nv.gov/>.

Notice of this meeting and draft copies of the changes will be available on or after the date of this notice at the DHCFP website <http://dhcfp.nv.gov/>. The agenda posting of this meeting can be viewed at the following locations: Carson City Central Office, Las Vegas District Office, Reno District Office and Elko District Office and may be reviewed during normal business hours.

If requested in writing, a draft copy of the changes will be mailed to you. Requests and/or written comments on the proposed changes may be sent to Jenifer Graham at the Division of Health Care Financing and Policy, 1100 E. William Street, Suite 101, Carson City, Nevada 89701.

All persons that have requested in writing to receive the public hearing agendas have been duly notified by mail or e-mail.

We are pleased to make accommodations for members of the public who have disabilities and wish to attend the meeting. If special arrangements are necessary, notify the Division of Health Care Financing and Policy as soon as possible and at least ten days in advance of the meeting, by e-mail

at: jenifer.graham@dncfp.nv.gov, in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Jenifer Graham at (775) 684-3685.
